SCHEMBL6415967

SCHEMBL6415967

CC(C)COC(=O)Nc1ccc(C#N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.56
LMNA P02545 5/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 2/20 0.49
MAPK1 P28482 2/20 0.49
SAE1 Q9UBE0 1/20 0.49
UBA2 Q9UBT2 1/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
IL18 Q14116 1/20 0.49
TSHR P16473 3/20 0.46
HTT P42858 3/20 0.46
NLRP3 Q96P20 1/20 0.46
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
ADRB3 P13945 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2323162 0.86 SMN1; SMN2 (0.57) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL2033732 0.83 RAB9A (0.56) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL3580483 0.82 SMN1; SMN2 (0.53) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL10192028 0.81 SMN1; SMN2 (0.61) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL2322638 0.81 SMN1; SMN2 (0.61) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL4421079 0.81 MMP2 (0.46) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL4421076 0.81 MMP2 (0.46) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL20073905 0.80 SMN1; SMN2 (0.51) SMN1; SMN2LMNAALDH1A1MAPTMAPK1
SCHEMBL14349323 0.80 LMNA (0.44) LMNAMAPTMAPK1SAE1UBA2
SCHEMBL14376088 0.80 SMN1; SMN2 (0.61) SMN1; SMN2LMNAALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101014343-A Tetracyclic lactam derivatives and uses thereof INOTEK PHARMACEUTICALS CORP (US) 2007-08-08 CN disclosed
US-20050261288-A1 Tetracyclic lactam derivatives and uses thereof INOTEK PHARMACEUTICALS CORPORATION 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261288-A1 Tetracyclic lactam derivatives and uses thereof PARK7, GLS, IAPP SMN1; SMN2 526/4885LMNA 4269/4885ALDH1A1 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.